权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Structure and dynamics of clinically-relevant cytochrome P450 enzymes

临床相关细胞色素 P450 酶的结构和动力学

基本信息

批准号：
10061625
负责人：
Thomas Charles Pochapsky
金额：
$ 42.91万
依托单位：
UNIVERSITY OF MICHIGAN AT ANN ARBOR
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-01-01 至 2022-11-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10061625
关键词：
Active Sites Affinity Amino Acids Anabolism Antineoplastic Agents Binding Binding Proteins Binding Sites CYP17A1 gene CYP2D6 gene CYP3A4 gene Catalysis Clinical Complex Crystallization Cytochrome P450 Cytochromes b5 Data Data Analyses Data Collection Disease Drug Design Drug Interactions Drug Targeting Elements Enzymes Evaluation Event Fatty Acids Goals Health Human Image Individual Infection Isotope Labeling Ligand Binding Ligands Malignant neoplasm of prostate Medical Membrane Metabolism Methods Mixed Function Oxygenases Molecular Conformation Oxides Oxidoreductase Pharmaceutical Preparations Play Prodrugs Prostate Protein Conformation Proteins Rationalization Research Research Personnel Resistance Roentgen Rays Steroid biosynthesis Structure Techniques Vitamins Work base clinically relevant design drug clearance drug development drug metabolism enzyme structure experience experimental study flexibility high risk human disease inhibitor/antagonist insight interest new technology oxidation polypeptide prevent protein complex scaffold small molecule

项目摘要

ABSTRACT Human cytochrome P450 enzymes are dynamic, often promiscuous, monooxygenases. Some function in the biosynthesis of critical endogenous compounds and are frequent drug targets. Others are dominant factors in drug metabolism, dictating drug clearance and/or prodrug activation. For both, understanding P450 interactions with substrates, inhibitors, and their catalytic partner proteins provides substantial useful information in drug design. While X-ray structures have provided numerous insights into drug binding to key human P450 enzymes, there are many gaps that cannot be filled by this approach. Conformational changes that P450s must undergo to channel ligands to the active site and for a single P450 to accommodate many different small molecule scaffolds only randomly become apparent in comparing the X-ray structures achievable. Despite substantial efforts, some key human P450 enzymes have not yielded to crystallization. Many drug substrates have lower active site affinity and/or multiple orientations not suitable to determining clear X-ray structures. There are no structures of human P450 enzymes with reductase or cytochrome b5 catalytic partners. As a result, drug design is limited by available structural information. We propose employing solution NMR as a newly-viable orthogonal method to obtain the requisite amino acid- level structural information needed to understand human P450/ligand and P450/protein interactions. While the size, stability, and the absence of information relating individual NMR resonances to the corresponding amino acid have all thus far prevented the determination of any human P450 structures by NMR, we have the combined expertise and preliminary data to demonstrate that this feat is now technically possible. The Pochapsky lab previously developed the expertise to determine solution NMR structures of slightly smaller, soluble bacterial P450 enzymes. The Scott lab developed the capacity to generate human membrane P450 enzymes in the isotopically-labeled forms, with the amounts and with the stability required for NMR experiments. Thus, based on substantial preliminary data, we propose to 1) advance strategies for determining human P450 structures by solution NMR while determining the human steroidogenic CYP17A1 structure and 2) apply solution NMR strategies to the two most important human drug-metabolizing P450 enzymes, CYP3A4 and CYP2D6. Successful completion of aim 1 will not only further establish the feasibility of NMR structures for human membrane P450 enzymes, but will do so for an important prostate cancer drug target for which additional structural information is essential to further drug design. Results of both aims will provide a reference set of amino acid assignments that can then be readily used by a wide range of non-NMR experts, in much simpler experiments, to quickly determine where and how drugs and other proteins bind to three clinically-important P450 enzymes, as well as deciphering the changes in protein conformation required for these events.

摘要